Ionis has confirmed that the therapy will be available in the US before the end of 2024. Credit: Ionis Pharmaceuticals, Inc. The US Food and
The partnership focuses on sialidase enzyme therapeutics in conjunction with Henlius’ rituximab. Credit: Jarun Ontakrai/Shutterstock. Palleon Pharmaceuticals and Shanghai Henlius Biotech have entered a licence
Sangamo’s STAC-BBB is known for its ability to penetrate the blood-brain barrier and transduce neurons. Credit: Komsan Loonprom/Shutterstock. Astellas Pharma and Sangamo Therapeutics have signed
The therapy is also under development for SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Credit: PowerUp/Shutterstock. Mesoblast has gained US Food and Drug Administration
The partnership aims to discover and validate therapeutic drug targets that address ageing-related diseases. Credit: Dragana Gordic/Shutterstock. BioAge Labs has entered a multi-year research partnership
Novo Nordisk has purchased three of Catalent’s fill-finish facilities from Novo Holdings. Credit: © 2024 Novo Nordisk A/S. Novo Holdings has completed the previously announced
The partnership aims to develop powder formulations of the vaccine candidates against influenza by leveraging Orexo’s AmorphOX technology. Credit: Ground Picture/Shutterstock. Abera Bioscience and Orexo
The partnership leverages Terray’s AI-driven platform designed to enhance drug discovery through high-throughput chemical experimentation. Credit: Collagery/Shutterstock. Gilead Sciences has entered a strategic partnership with
The collaboration of Lilly and EVA Pharma began in 2022 to provide affordable insulin. Credit: © 2022 Eva Pharma All Rights Reserved. Eli Lilly and
The approval marks the first indication of MSD’s KEYTRUDA in the earlier stages of NSCLC in China. Credit: JHVEPhoto/Shutterstock. China National Medical Products Administration (NMPA)